Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...
Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth
Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder...
Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...
FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma
An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...
Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...
AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline
AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt...
KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma
Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...
Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...
Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma
Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...
Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults
The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...
Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia
Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in...
CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars
The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...
CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure
The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two...
BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that...
Innovent Biologics Denies Lab Closure, Confirms Relocation to California
Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...
Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...
BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift
The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...
European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...